REG - Silence Therapeutics - Result of General Meeting

Silence TherapeuticsAnnouncement

01/11/2021 17:35

RNS Number : 9809Q
  
Silence Therapeutics PLC
  
01 November 2021
  
 

 
 
Results of General Meeting
1 November 2021
 
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general meeting held today, 1 November 2021, all resolutions set out in the notice of meeting were duly passed on a poll. 
 
The votes were as follows:
 



Special Resolution


Votes for


%


Votes against


%


Votes total


% of ISC voted


Votes withheld




1 - Approve the cancellation of the admission to trading on AIM of the ordinary shares of nominal value £0.05 each in the capital of the Company and authorise the directors of the Company to take all action reasonable or necessary to effect such cancellation


31,092,066
 


99.47
 
 


166,904
 
 


0.53
 
 


31,258,970
 
 


34.82
 
 


4,408,363
 
 




2 - Approve, conditional on the passing of Resolution 1, the amendment to the articles of association of the Company


31,354,885


99.89


34,007


0.11


31,388,892


35.00


4,278,441



 
The number of the Company's ordinary shares in issue as at the date of the meeting was 89,784,720 ordinary shares of nominal value £0.05 each.
 
A vote withheld is not a vote in law and has not been counted in the total votes or the calculation of the proportion of votes for and against the resolutions.
 
The Company confirms that, as at today's date, the timetable for the cancellation of the admission to trading on AIM of the Company's ordinary shares is as follows:
 



Last date for receipt by Link Group from certificated shareholders of duly completed block transfer participation request forms and original share certificates


3 November 2021 at 1.00 p.m.














Last date for receipt by The Bank of New York Mellon from CREST holders of duly completed issuance forms


17 November 2021 at 3.00 p.m.














Expected date of issuance of ADSs to block transfer participants


24 November 2021














Expected date of posting of ADS confirmations to shareholders by The Bank of New York Mellon


24 November 2021














Last day of dealings in the Ordinary Shares on AIM


29 November 2021














Cancellation of admission to trading on AIM of the Ordinary Shares


30 November 2021 at 7.00 a.m.



 
 
 
Enquiries:
 



Silence Therapeutics plc
 Gem Hopkins, Head of IR & Corporate Communications


Tel:  +1 (646) 637-3208




 
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


 
Tel:  +44 (0) 20 7597 5970




European PR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
 


Tel: +44 (0) 20 3709 5700



 
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ROMDFLFBFFLLFBK